Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M

ROCKWELL MEDICAL, INC.

2025-FY EPS reported -$0.15 revenue$69,258,000

Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).
Gross margin improved to ~22% in Q4, up from 14% in Q3 2025.
Q4 cash flow from operations ~$2.3M, second cash-positive quarter; cash & equivalents ~$25M at year-end.
CEO highlighted revenue growth, increased profitability, and portfolio diversification as 2026 focus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.